A-HeFT trial: positive results
This article has no abstract so we have provided the first paragraph of the full text.
In the first Vasodilator Heart Failure Trial (V-HeFT), the combination of the antioxidant hydralazine with isosorbide dinitrate—which stimulates nitric oxide signaling—was beneficial in patients with mild to severe heart failure. Since then, subgroup analysis of previous trial data has indicated that black patients respond particularly well to this drug combination. The African-American Heart Failure Trial (A-HeFT) studied the efficacy of a fixed dose of isosorbide dinitrate and hydralazine in black patients with advanced heart failure.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
